Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 25.250
Filtrer
1.
Molecules ; 29(12)2024 Jun 17.
Article de Anglais | MEDLINE | ID: mdl-38930939

RÉSUMÉ

Atherosclerosis continues to be a leading cause of morbidity and mortality globally. The precise evaluation of the extent of an atherosclerotic plaque is essential for forecasting its likelihood of causing health concerns and tracking treatment outcomes. When compared to conventional methods used, nanoparticles offer clear benefits and excellent development opportunities for the detection and characterisation of susceptible atherosclerotic plaques. In this review, we analyse the recent advancements of nanoparticles as theranostics in the management of atherosclerosis, with an emphasis on applications in drug delivery. Furthermore, the main issues that must be resolved in order to advance clinical utility and future developments of NP research are discussed. It is anticipated that medical NPs will develop into complex and advanced next-generation nanobotics that can carry out a variety of functions in the bloodstream.


Sujet(s)
Athérosclérose , Systèmes de délivrance de médicaments , Nanoparticules , Humains , Athérosclérose/traitement médicamenteux , Nanoparticules/composition chimique , Systèmes de délivrance de médicaments/méthodes , Animaux , Nanomédecine théranostique/méthodes , Plaque d'athérosclérose/traitement médicamenteux , Vecteurs de médicaments/composition chimique
2.
AAPS PharmSciTech ; 25(6): 148, 2024 Jun 27.
Article de Anglais | MEDLINE | ID: mdl-38937387

RÉSUMÉ

Our study aimed to explore the potential of using nanostructured lipid carriers (NLCs) to enhance the topical administration of ß-sitosterol, a bioactive that is poorly soluble in water. Here, we have taken advantage of the unique characteristics that cubosomes have to provide as a drug delivery system. These characteristics include a large surface area, thermal stability, and the capacity to encapsulate molecules that are hydrophobic, amphiphilic, and hydrophilic. The cubosomal formulation was optimized by building a central composite design. The optimum dispersion exhibited a particle size of 88.3 nm, a zeta potential of -43, a polydispersity index of 0.358, and drug entrapment of 95.6%. It was composed of 15% w/w oleic acid and 5% w/w pluronic F127. The optimized cubosome dispersion was incorporated into a sponge formulation. The optimized cubosome sponge achieved a higher drug release compared with the cubosome dispersion. The SEM micrograph of the selected sponge showed that it has an interwoven irregular fibrous lamellar structure with low density and high porosity. The in-vivo data revealed that topical application of the ß-sitosterol cubosomal sponge showed significant higher wound closure percentage relative to the ß-sitosterol product (Mebo)®.


Sujet(s)
Brûlures , Chitosane , Vecteurs de médicaments , Taille de particule , Sitostérol , Sitostérol/composition chimique , Sitostérol/administration et posologie , Animaux , Chitosane/composition chimique , Vecteurs de médicaments/composition chimique , Brûlures/traitement médicamenteux , Libération de médicament , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Mâle , Systèmes de délivrance de médicaments/méthodes , Rats , Poloxamère/composition chimique , Interactions hydrophobes et hydrophiles , Nanostructures/composition chimique , Administration par voie topique
3.
AAPS PharmSciTech ; 25(6): 146, 2024 Jun 27.
Article de Anglais | MEDLINE | ID: mdl-38937416

RÉSUMÉ

Oleogels is a novel semi-solid system, focusing on its composition, formulation, characterization, and diverse pharmaceutical applications. Due to their stability, smoothness, and controlled release qualities, oleogels are frequently utilized in food, cosmetics, and medicinal products. Oleogels are meticulously formulated by combining oleogelators like waxes, fatty acids, ethyl cellulose, and phytosterols with edible oils, leading to a nuanced understanding of their impact on rheological characteristics. They can be characterized by methods like visual inspection, texture analysis, rheological measurements, gelation tests, and microscopy. The applications of oleogels are explored in diverse fields such as nutraceuticals, cosmetics, food, lubricants, and pharmaceutics. Oleogels have applications in topical, transdermal, and ocular drug delivery, showcasing their potential for revolutionizing drug administration. This review aims to enhance the understanding of oleogels, contributing to the evolving landscape of pharmaceutical formulations. Oleogels emerge as a versatile and promising solution, offering substantial potential for innovation in drug delivery and formulation practices.


Sujet(s)
Systèmes de délivrance de médicaments , Composés chimiques organiques , Composés chimiques organiques/composition chimique , Systèmes de délivrance de médicaments/méthodes , Chimie pharmaceutique/méthodes , Rhéologie , Préparations pharmaceutiques/composition chimique , Préparation de médicament/méthodes
4.
J Nanobiotechnology ; 22(1): 371, 2024 Jun 25.
Article de Anglais | MEDLINE | ID: mdl-38918805

RÉSUMÉ

The gut microbiota is one of the essential contributors of the pathogenesis and progress of inflammatory bowel disease (IBD). Compared with first-line drug therapy, probiotic supplementation has emerged as a viable and secure therapeutic approach for managing IBD through the regulation of both the immune system and gut microbiota. Nevertheless, the efficacy of oral probiotic supplements is hindered by their susceptibility to the gastrointestinal barrier, leading to diminished bioavailability and restricted intestinal colonization. Here, we developed a bacteria-microalgae symbiosis system (EcN-SP) for targeted intestinal delivery of probiotics and highly effective treatment of colitis. The utilization of mircroalge Spirulina platensis (SP) as a natural carrier for the probiotic Escherichia coli Nissle 1917 (EcN) demonstrated potential benefits in promoting EcN proliferation, facilitating effective intestinal delivery and colonization. The alterations in the binding affinity of EcN-SP within the gastrointestinal environment, coupled with the distinctive structural properties of the SP carrier, served to overcome gastrointestinal barriers, minimizing transgastric EcN loss and enabling sustained intestinal retention and colonization. The oral administration of EcN-SP could effectively treat IBD by reducing the expression of intestinal inflammatory factors, maintaining the intestinal barrier and regulating the balance of gut microbiota. This probiotic delivery approach is inspired by symbiotic interactions found in nature and offers advantages in terms of feasibility, safety, and efficacy, thus holding significant promise for the management of gastrointestinal disorders.


Sujet(s)
Escherichia coli , Microbiome gastro-intestinal , Microalgues , Probiotiques , Spirulina , Symbiose , Animaux , Souris , Maladies inflammatoires intestinales/microbiologie , Maladies inflammatoires intestinales/thérapie , Humains , Colite , Souris de lignée C57BL , Mâle , Systèmes de délivrance de médicaments/méthodes
5.
J Nanobiotechnology ; 22(1): 372, 2024 Jun 25.
Article de Anglais | MEDLINE | ID: mdl-38918811

RÉSUMÉ

Hemangioma of infancy is the most common vascular tumor during infancy and childhood. Despite the proven efficacy of propranolol treatment, certain patients still encounter resistance or face recurrence. The need for frequent daily medication also poses challenges to patient adherence. Bleomycin (BLM) has demonstrated effectiveness against vascular anomalies, yet its use is limited by dose-related complications. Addressing this, this study proposes a novel approach for treating hemangiomas using BLM-loaded hyaluronic acid (HA)-based microneedle (MN) patches. BLM is encapsulated during the synthesis of polylactic acid (PLA) microspheres (MPs). The successful preparation of PLA MPs and MN patches is confirmed through scanning electron microscopy (SEM) images. The HA microneedles dissolve rapidly upon skin insertion, releasing BLM@PLA MPs. These MPs gradually degrade within 28 days, providing a sustained release of BLM. Comprehensive safety assessments, including cell viability, hemolysis ratio, and intradermal reactions in rabbits, validate the safety of MN patches. The BLM@PLA-MNs exhibit an effective inhibitory efficiency against hemangioma formation in a murine hemangioma model. Of significant importance, RNA-seq analysis reveals that BLM@PLA-MNs exert their inhibitory effect on hemangiomas by regulating the P53 pathway. In summary, BLM@PLA-MNs emerge as a promising clinical candidate for the effective treatment of hemangiomas.


Sujet(s)
Bléomycine , Préparations à action retardée , Systèmes de délivrance de médicaments , Hémangiome , Acide hyaluronique , Aiguilles , Polyesters , Bléomycine/pharmacologie , Animaux , Souris , Lapins , Hémangiome/traitement médicamenteux , Acide hyaluronique/composition chimique , Préparations à action retardée/composition chimique , Systèmes de délivrance de médicaments/méthodes , Polyesters/composition chimique , Humains , Microsphères , Antibiotiques antinéoplasiques/pharmacologie , Antibiotiques antinéoplasiques/usage thérapeutique , Antibiotiques antinéoplasiques/administration et posologie , Antibiotiques antinéoplasiques/pharmacocinétique , Libération de médicament
6.
J Nanobiotechnology ; 22(1): 365, 2024 Jun 25.
Article de Anglais | MEDLINE | ID: mdl-38918839

RÉSUMÉ

Bacteriophages (phages) represent a unique category of viruses with a remarkable ability to selectively infect host bacteria, characterized by their assembly from proteins and nucleic acids. Leveraging their exceptional biological properties and modifiable characteristics, phages emerge as innovative, safe, and efficient delivery vectors. The potential drawbacks associated with conventional nanocarriers in the realms of drug and gene delivery include a lack of cell-specific targeting, cytotoxicity, and diminished in vivo transfection efficiency. In contrast, engineered phages, when employed as cargo delivery vectors, hold the promise to surmount these limitations and attain enhanced delivery efficacy. This review comprehensively outlines current strategies for the engineering of phages, delineates the principal types of phages utilized as nanocarriers in drug and gene delivery, and explores the application of phage-based delivery systems in disease therapy. Additionally, an incisive analysis is provided, critically examining the challenges confronted by phage-based delivery systems within the domain of nanotechnology. The primary objective of this article is to furnish a theoretical reference that contributes to the reasoned design and development of potent phage-based delivery systems.


Sujet(s)
Bactériophages , Systèmes de délivrance de médicaments , Nanomédecine , Bactériophages/génétique , Humains , Nanomédecine/méthodes , Systèmes de délivrance de médicaments/méthodes , Animaux , Techniques de transfert de gènes , Vecteurs de médicaments/composition chimique , Nanoparticules/composition chimique , Nanotechnologie/méthodes
7.
Cells ; 13(12)2024 Jun 07.
Article de Anglais | MEDLINE | ID: mdl-38920629

RÉSUMÉ

The world of cancer treatment is evolving rapidly and has improved the prospects of many cancer patients. Yet, there are still many cancers where treatment prospects have not (or hardly) improved. Glioblastoma is the most common malignant primary brain tumor, and even though it is sensitive to many chemotherapeutics when tested under laboratory conditions, its clinical prospects are still very poor. The blood-brain barrier (BBB) is considered at least partly responsible for the high failure rate of many promising treatment strategies. We describe the workings of the BBB during healthy conditions and within the glioblastoma environment. How the BBB acts as a barrier for therapeutic options is described as well as various approaches developed and tested for passing or opening the BBB, with the ultimate aim to allow access to brain tumors and improve patient perspectives.


Sujet(s)
Barrière hémato-encéphalique , Tumeurs du cerveau , Systèmes de délivrance de médicaments , Glioblastome , Glioblastome/traitement médicamenteux , Glioblastome/anatomopathologie , Humains , Barrière hémato-encéphalique/métabolisme , Barrière hémato-encéphalique/effets des médicaments et des substances chimiques , Systèmes de délivrance de médicaments/méthodes , Tumeurs du cerveau/traitement médicamenteux , Tumeurs du cerveau/anatomopathologie , Antinéoplasiques/usage thérapeutique , Antinéoplasiques/pharmacologie , Antinéoplasiques/administration et posologie , Animaux
8.
J Control Release ; 371: 530-554, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38857787

RÉSUMÉ

Wound management remains a great challenge for clinicians due to the complex physiological process of wound healing. Porous silicon (PSi) with controlled pore morphology, abundant surface chemistry, unique photonic properties, good biocompatibility, easy biodegradation and potential bioactivity represent an exciting class of materials for various biomedical applications. In this review, we focus on the recent progress of PSi in the design of advanced sensing and delivery systems for wound management applications. Firstly, we comprehensively introduce the common type, normal healing process, delaying factors and therapeutic drugs of wound healing. Subsequently, the typical fabrication, functionalization and key characteristics of PSi have been summarized because they provide the basis for further use as biosensing and delivery materials in wound management. Depending on these properties, the rise of PSi materials is evidenced by the examples in literature in recent years, which has emphasized the robust potential of PSi for wound monitoring, treatment and theranostics. Finally, challenges and opportunities for the future development of PSi-based sensors and delivery systems for wound management applications are proposed and summarized. We hope that this review will help readers to better understand current achievements and future prospects on PSi-based sensing and delivery systems for advanced wound management.


Sujet(s)
Systèmes de délivrance de médicaments , Silicium , Cicatrisation de plaie , Silicium/composition chimique , Humains , Porosité , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Animaux , Systèmes de délivrance de médicaments/méthodes , Techniques de biocapteur/méthodes
9.
Transl Vis Sci Technol ; 13(6): 12, 2024 Jun 03.
Article de Anglais | MEDLINE | ID: mdl-38888287

RÉSUMÉ

Purpose: Recombinant human nerve growth factor (rhNGF; cenegermin-bkbj, OXERVATE) is the first and only U.S. Food and Drug Administration-approved treatment for moderate to severe neurotrophic keratopathy. The aim of this study was to determine the feasibility of incorporating a version of rhNGF in a mucoadhesive hydrogel capable of sustained drug release to the ocular surface. Methods: Hydrogels loaded with rhNGF were synthesized by conjugating chitosan with azidobenzoic acid (Az-Ch), adding rhNGF, and exposing the solution to ultraviolet (UV) radiation to induce photocrosslinking. Az-Ch hydrogels were evaluated for physical properties and rhNGF release profiles. Cytocompatbility of Az-Ch was assessed using immortalized human corneal limbal epithelial (HCLE) cells. TF1 erythroleukemic cell proliferation and HCLE cell proliferation and migration were used to assess the bioactivity of rhNGF released from Az-Ch hydrogels. Results: Az-Ch formed hydrogels in <10 seconds of UV exposure and demonstrated high optical transparency (75-85 T%). Az-Ch hydrogels exhibited good cytocompatibility with no demonstratable effect on HCLE cell morphology or viability. rhNGF was released gradually over 24 hours from Az-Ch hydrogels and retained its ability to induce TF1 cell proliferation. No significant difference was observed between rhNGF released from Az-Ch and freshly prepared rhNGF solutions on HCLE cell proliferation or percent wound closure after 12 hours; however, both were significantly better than control (P < 0.01). Conclusions: rhNGF-loaded Az-Ch hydrogels exhibited favorable physical, optical, and drug-release properties, as well as retained drug bioactivity. This drug delivery system has the potential to be further developed for in vivo and translational clinical applications. Translational Relevance: Az-Ch hydrogels may be used to enhance rhNGF therapy in patients with NK.


Sujet(s)
Prolifération cellulaire , Chitosane , Hydrogels , Facteur de croissance nerveuse , Facteur de croissance nerveuse/pharmacologie , Facteur de croissance nerveuse/composition chimique , Facteur de croissance nerveuse/administration et posologie , Humains , Chitosane/composition chimique , Chitosane/pharmacologie , Hydrogels/composition chimique , Hydrogels/pharmacologie , Hydrogels/synthèse chimique , Prolifération cellulaire/effets des médicaments et des substances chimiques , Mouvement cellulaire/effets des médicaments et des substances chimiques , Rayons ultraviolets , Réactifs réticulants/composition chimique , Limbe de la cornée/effets des médicaments et des substances chimiques , Limbe de la cornée/cytologie , Protéines recombinantes/composition chimique , Systèmes de délivrance de médicaments/méthodes
10.
Int J Nanomedicine ; 19: 6295-6317, 2024.
Article de Anglais | MEDLINE | ID: mdl-38919774

RÉSUMÉ

Nanoscale metal-organic frameworks (MOFs) offer high biocompatibility, nanomaterial permeability, substantial specific surface area, and well-defined pores. These properties make MOFs valuable in biomedical applications, including biological targeting and drug delivery. They also play a critical role in tumor diagnosis and treatment, including tumor cell targeting, identification, imaging, and therapeutic methods such as drug delivery, photothermal effects, photodynamic therapy, and immunogenic cell death. The diversity of MOFs with different metal centers, organics, and surface modifications underscores their multifaceted contributions to tumor research and treatment. This review is a summary of these roles and mechanisms. The final section of this review summarizes the current state of the field and discusses prospects that may bring MOFs closer to pharmaceutical applications.


Sujet(s)
Réseaux organométalliques , Nanocomposites , Tumeurs , Réseaux organométalliques/composition chimique , Humains , Tumeurs/imagerie diagnostique , Tumeurs/thérapie , Nanocomposites/composition chimique , Nanocomposites/usage thérapeutique , Systèmes de délivrance de médicaments/méthodes , Animaux , Photothérapie dynamique/méthodes , Antinéoplasiques/composition chimique , Nanomédecine/méthodes
11.
Biomed Pharmacother ; 176: 116904, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38878686

RÉSUMÉ

Globally, cancer is a serious health problem. It is unfortunate that current anti-cancer strategies are insufficiently specific and damage the normal tissues. There's urgent need for development of new anti-cancer strategies. More recently, increasing attention has been paid to the new application of ferroptosis and nano materials in cancer research. Ferroptosis, a condition characterized by excessive reactive oxygen species-induced lipid peroxidation, as a new programmed cell death mode, exists in the process of a number of diseases, including cancers, neurodegenerative disease, cerebral hemorrhage, liver disease, and renal failure. There is growing evidence that inducing ferroptosis has proven to be an effective strategy against a variety of chemo-resistant cancer cells. Nano-drug delivery system based on nanotechnology provides a highly promising platform with the benefits of precise control of drug release and reduced toxicity and side effects. This paper reviews the latest advances of combination therapy strategies based on biomedical nanotechnology induced ferroptosis for cancer therapeutics. Given the new chances and challenges in this emerging area, we need more attention to the combination of nanotechnology and ferroptosis in the treatment of cancer in the future.


Sujet(s)
Ferroptose , Tumeurs , Ferroptose/effets des médicaments et des substances chimiques , Humains , Tumeurs/traitement médicamenteux , Tumeurs/anatomopathologie , Animaux , Antinéoplasiques/pharmacologie , Antinéoplasiques/administration et posologie , Nanoparticules , Nanotechnologie/méthodes , Système d'administration de médicaments à base de nanoparticules , Systèmes de délivrance de médicaments/méthodes , Association thérapeutique , Espèces réactives de l'oxygène/métabolisme , Nanomédecine/méthodes
12.
Int J Nanomedicine ; 19: 5859-5878, 2024.
Article de Anglais | MEDLINE | ID: mdl-38887691

RÉSUMÉ

Mesoporous silica nanoparticles (MSNs) have attracted extensive attention as drug delivery systems because of their unique meso-structural features (high specific surface area, large pore volume, and tunable pore structure), easily modified surface, high drug-loading capacity, and sustained-release profiles. However, the enduring and non-specific enrichment of MSNs in healthy tissues may lead to toxicity due to their slow degradability and hinder their clinical application. The emergence of degradable MSNs provided a solution to this problem. The understanding of strategies to regulate degradation and clearance of these MSNs for promoting clinical trials and expanding their biological applications is essential. Here, a diverse variety of degradable MSNs regarding considerations of physiochemical properties and doping strategies of degradation, the biodistribution of MSNs in vivo, internal clearance mechanism, and adjusting physical parameters of clearance are highlighted. Finally, an overview of these degradable and clearable MSNs strategies for biosafety is provided along with an outlook of the encountered challenges.


Sujet(s)
Nanoparticules , Silice , Silice/composition chimique , Silice/pharmacocinétique , Porosité , Nanoparticules/composition chimique , Humains , Distribution tissulaire , Animaux , Vecteurs de médicaments/composition chimique , Vecteurs de médicaments/pharmacocinétique , Systèmes de délivrance de médicaments/méthodes
13.
Int J Nanomedicine ; 19: 5931-5949, 2024.
Article de Anglais | MEDLINE | ID: mdl-38887690

RÉSUMÉ

The self-assembling aggregated structures of natural products have gained significant interest due to their simple synthesis, lack of carrier-related toxicity, and excellent biological efficacy. However, the mechanisms of their assembly and their ability to traverse the gastrointestinal (GI) barrier remain unclear. This review summarizes various intermolecular non-covalent interactions and aggregated structures, drawing on research indexed in Web of Science from 2010 to 2024. Cheminformatics analysis of the self-assembly behaviors of natural small molecules and their supramolecular aggregates reveals assembly-favorable conditions, aiding drug formulation. Additionally, the review explores the self-assembly properties of macromolecules like polysaccharides, proteins, and exosomes, highlighting their role in drug delivery. Strategies to overcome gastrointestinal barriers and enhance drug bioavailability are also discussed. This work underscores the potential of natural products in oral drug delivery and offers insights for designing more effective drug delivery systems.


Sujet(s)
Produits biologiques , Systèmes de délivrance de médicaments , Produits biologiques/composition chimique , Produits biologiques/pharmacocinétique , Produits biologiques/administration et posologie , Humains , Administration par voie orale , Systèmes de délivrance de médicaments/méthodes , Biodisponibilité , Polyosides/composition chimique , Polyosides/pharmacocinétique , Vecteurs de médicaments/composition chimique , Vecteurs de médicaments/pharmacocinétique , Animaux , Tube digestif/métabolisme , Exosomes/composition chimique
14.
Pharmacol Res Perspect ; 12(4): e1168, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38894611

RÉSUMÉ

Bioengineering and drug delivery technologies play an important role in bridging the gap between basic scientific discovery and clinical application of therapeutics. To identify the optimal treatment, the most critical stage is to diagnose the problem. Often these two may occur simultaneously or in parallel, but in this review, we focus on bottom-up approaches in understanding basic immunologic phenomena to develop targeted therapeutics. This can be observed in several fields; here, we will focus on one of the original immunotherapy targets-cancer-and one of the more recent targets-regenerative medicine. By understanding how our immune system responds in processes such as malignancies, wound healing, and medical device implantation, we can isolate therapeutic targets for pharmacologic and bioengineered interventions.


Sujet(s)
Bioingénierie , Systèmes de délivrance de médicaments , Immunothérapie , Tumeurs , Médecine régénérative , Humains , Animaux , Bioingénierie/méthodes , Tumeurs/immunologie , Tumeurs/thérapie , Immunothérapie/méthodes , Médecine régénérative/méthodes , Systèmes de délivrance de médicaments/méthodes
15.
Int J Mol Sci ; 25(12)2024 Jun 13.
Article de Anglais | MEDLINE | ID: mdl-38928229

RÉSUMÉ

Collagen, a versatile family of proteins with 28 members and 44 genes, is pivotal in maintaining tissue integrity and function. It plays a crucial role in physiological processes like wound healing, hemostasis, and pathological conditions such as fibrosis and cancer. Collagen is a target in these processes. Direct methods for collagen modulation include enzymatic breakdown and molecular binding approaches. For instance, Clostridium histolyticum collagenase is effective in treating localized fibrosis. Polypeptides like collagen-binding domains offer promising avenues for tumor-specific immunotherapy and drug delivery. Indirect targeting of collagen involves regulating cellular processes essential for its synthesis and maturation, such as translation regulation and microRNA activity. Enzymes involved in collagen modification, such as prolyl-hydroxylases or lysyl-oxidases, are also indirect therapeutic targets. From another perspective, collagen is also a natural source of drugs. Enzymatic degradation of collagen generates bioactive fragments known as matrikines and matricryptins, which exhibit diverse pharmacological activities. Overall, collagen-derived peptides present significant therapeutic potential beyond tissue repair, offering various strategies for treating fibrosis, cancer, and genetic disorders. Continued research into specific collagen targeting and the application of collagen and its derivatives may lead to the development of novel treatments for a range of pathological conditions.


Sujet(s)
Collagène , Humains , Collagène/métabolisme , Animaux , Tumeurs/traitement médicamenteux , Tumeurs/métabolisme , Tumeurs/anatomopathologie , Fibrose , Systèmes de délivrance de médicaments/méthodes
16.
Int J Mol Sci ; 25(12)2024 Jun 14.
Article de Anglais | MEDLINE | ID: mdl-38928262

RÉSUMÉ

Cancer is a significant global public health issue with increasing morbidity and mortality rates. To address this challenge, novel drug carriers such as nano-materials, liposomes, hydrogels, fibers, and microspheres have been extensively researched and utilized in oncology. Among them, polymer microspheres are gaining popularity due to their ease of preparation, excellent performance, biocompatibility, and drug-release capabilities. This paper categorizes commonly used materials for polymer microsphere preparation, summarizes various preparation methods (emulsification, phase separation, spray drying, electrospray, microfluidics, and membrane emulsification), and reviews the applications of polymer microspheres in cancer diagnosis, therapy, and postoperative care. The current status and future development directions of polymer microspheres in cancer treatment are analyzed, highlighting their importance and potential for improving patient outcomes.


Sujet(s)
Microsphères , Tumeurs , Polymères , Humains , Tumeurs/diagnostic , Tumeurs/thérapie , Polymères/composition chimique , Vecteurs de médicaments/composition chimique , Animaux , Antinéoplasiques/usage thérapeutique , Systèmes de délivrance de médicaments/méthodes
17.
Int J Mol Sci ; 25(12)2024 Jun 18.
Article de Anglais | MEDLINE | ID: mdl-38928403

RÉSUMÉ

Despite the recognized potential of nanoparticles, only a few formulations have progressed to clinical trials, and an even smaller number have been approved by the regulatory authorities and marketed. Virus-like particles (VLPs) have emerged as promising alternatives to conventional nanoparticles due to their safety, biocompatibility, immunogenicity, structural stability, scalability, and versatility. Furthermore, VLPs can be surface-functionalized with small molecules to improve circulation half-life and target specificity. Through the functionalization and coating of VLPs, it is possible to optimize the response properties to a given stimulus, such as heat, pH, an alternating magnetic field, or even enzymes. Surface functionalization can also modulate other properties, such as biocompatibility, stability, and specificity, deeming VLPs as potential vaccine candidates or delivery systems. This review aims to address the different types of surface functionalization of VLPs, highlighting the more recent cutting-edge technologies that have been explored for the design of tailored VLPs, their importance, and their consequent applicability in the medical field.


Sujet(s)
Vaccins à pseudo-particules virales , Humains , Vaccins à pseudo-particules virales/immunologie , Nanoparticules/composition chimique , Animaux , Virion/composition chimique , Systèmes de délivrance de médicaments/méthodes
18.
Curr Opin Anaesthesiol ; 37(4): 362-370, 2024 Aug 01.
Article de Anglais | MEDLINE | ID: mdl-38841991

RÉSUMÉ

PURPOSE OF REVIEW: The drug titration paradox describes that, from a population standpoint, drug doses appear to have a negative correlation with its clinical effect. This paradox is a relatively modern discovery in anesthetic pharmacology derived from large clinical data sets. This review will interpret the paradox using a control engineering perspective. RECENT FINDINGS: Drug titration is a challenging endeavor, and the medication delivery systems used in everyday clinical practice, including infusion pumps and vaporizers, typically do not allow for rapid or robust titration of medication being delivered. In addition, clinicians may be reluctant to deviate from a predetermined plan or may be content to manage patients within fixed goal boundaries. SUMMARY: This drug titration paradox describes the constraints of how the average clinician will dose a patient with an unknown clinical response. While our understanding of the paradox is still in its infancy, it remains unclear how alternative dosing schemes, such as through automation, may exceed the boundaries of the paradox and potentially affect its conclusions.


Sujet(s)
Anesthésiques , Humains , Anesthésiques/administration et posologie , Systèmes de délivrance de médicaments/méthodes , Relation dose-effet des médicaments , Pompes à perfusion/normes
19.
J Nanobiotechnology ; 22(1): 354, 2024 Jun 20.
Article de Anglais | MEDLINE | ID: mdl-38902775

RÉSUMÉ

Fundus neovascularization diseases are a series of blinding eye diseases that seriously impair vision worldwide. Currently, the means of treating these diseases in clinical practice are continuously evolving and have rapidly revolutionized treatment opinions. However, key issues such as inadequate treatment effectiveness, high rates of recurrence, and poor patient compliance still need to be urgently addressed. Multifunctional nanomedicine can specifically respond to both endogenous and exogenous microenvironments, effectively deliver drugs to specific targets and participate in activities such as biological imaging and the detection of small molecules. Nano-in-micro (NIM) delivery systems such as metal, metal oxide and up-conversion nanoparticles (NPs), quantum dots, and carbon materials, have shown certain advantages in overcoming the presence of physiological barriers within the eyeball and are widely used in the treatment of ophthalmic diseases. Few studies, however, have evaluated the efficacy of NIM delivery systems in treating fundus neovascular diseases (FNDs). The present study describes the main clinical treatment strategies and the adverse events associated with the treatment of FNDs with NIM delivery systems and summarizes the anatomical obstacles that must be overcome. In this review, we wish to highlight the principle of intraocular microenvironment normalization, aiming to provide a more rational approach for designing new NIM delivery systems to treat specific FNDs.


Sujet(s)
Systèmes de délivrance de médicaments , Humains , Animaux , Systèmes de délivrance de médicaments/méthodes , Néovascularisation pathologique/traitement médicamenteux , Fond de l'oeil , Boîtes quantiques/composition chimique , Nanoparticules multifonctionnelles/composition chimique , Néovascularisation rétinienne/traitement médicamenteux , Nanomédecine/méthodes , Nanoparticules/composition chimique
20.
Arch Dermatol Res ; 316(6): 316, 2024 Jun 01.
Article de Anglais | MEDLINE | ID: mdl-38822884

RÉSUMÉ

In the present study, we have formulated a methotrexate (MTX)-loaded microemulsion topical gel employing quality-by-design optimization. The optimized lipid-based microemulsion was incorporated into a 2% carbopol gel. The prepared formulation was characterized for micromeritics, surface charge, surface morphology, conductivity studies, rheology studies, texture analysis/spreadability, drug entrapment, and drug loading studies. The formulation was further evaluated for drug release and release kinetics, cytotoxicity assays, drug permeation and drug retention studies, and dermatokinetics. The developed nanosystem was not only rheologically acceptable but also offered substantial drug entrapment and loading. From drug release studies, it was observed that the nanogel showed higher drug release at pH 5.0 compared to plain MTX, plain gel, and plain microemulsion. The developed system with improved dermatokinetics, nanometric size, higher drug loading, and enhanced efficacy towards A314 squamous epithelial cells offers a huge promise in the topical delivery of methotrexate.


Sujet(s)
Libération de médicament , Émulsions , Gels , Méthotrexate , Absorption cutanée , Méthotrexate/administration et posologie , Méthotrexate/composition chimique , Méthotrexate/pharmacocinétique , Humains , Absorption cutanée/effets des médicaments et des substances chimiques , Rhéologie , Lipides/composition chimique , Administration par voie cutanée , Peau/métabolisme , Peau/effets des médicaments et des substances chimiques , Administration par voie topique , Systèmes de délivrance de médicaments/méthodes , Animaux , Taille de particule , Vecteurs de médicaments/composition chimique , Nanogels/composition chimique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...